LHHealthcare · Diagnostics & ResearchThe 18 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $350 — +9.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 8 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $300 → $309 |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $330 → $360 |
| 31 July 2026 | Barclays | Maintains | Equal-Weight | $290 → $320 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | $308 → $338 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $320 → $350 |
| 13 July 2026 | B of A Securities | Maintains | Buy | — |
| 13 July 2026 | B of A Securities | Maintains | Buy | $300 → $320 |
| 13 July 2026 | Baird | Maintains | Outperform | $335 → $338 |
| 13 July 2026 | Baird | Maintains | Outperform | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 24 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 18 Feb 2026 | Baird | Maintains | Outperform | — |
| 18 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 29 Oct 2025 | UBS | Maintains | Buy | — |
| 17 Oct 2025 | Mizuho | Maintains | Outperform | — |
| 17 Oct 2025 | UBS | Maintains | Buy | — |
| 3 Oct 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, Labcorp Holdings, Inc. returned +16.6% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 55% of US stocks
Cheaper than 33% of US stocks
Cheaper than 25% of US stocks
Higher than 41% of US stocks
Higher than 63% of US stocks
Higher than 34% of US stocks
Higher than 68% of US stocks
Higher than 64% of US stocks
Higher than 67% of US stocks
Higher than 79% of US stocks
Higher than 20% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Labcorp Holdings, Inc. has a market value of $26.0B and an enterprise value of $32.7B.
Revenue in the twelve months to 30 June 2026: $14.3B. The latest quarter grew 5.8% year on year.
Net income over the same four quarters: $1.0B, a 7.0% net margin.
Diluted earnings per share, trailing twelve months: $12.09.
Free cash flow in the twelve months to 30 June 2026: $1.2B, after $483.2M of capital spending.
Labcorp Holdings, Inc. spent $701.8M on share buybacks and $239.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 26.9×; forward P/E: 16.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.90%, paying out 24% of earnings.
Labcorp Holdings, Inc. employs 71,000 people — $202K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Great Point Partners announced it has sold its portfolio company MLM Medical Labs, a provider of global central and specialty lab services supporting clinical trials, biomarker testing, and drug development, to Labcorp.
Why it matters — The acquisition expands Labcorp's central and specialty laboratory services in the life sciences and biopharma drug development space.
Moonwalk Biosciences announced a $70 million Series B funding round, with NYSE issuing a pre-market daily advisory from the trading floor. The announcement was distributed via PRNewsWire as a NYSE content update.
Why it matters — A LH watcher would care because this NYSE content update and related market advisory could signal broader market activity relevant to Labcorp Holdings.
Labcorp announced the acquisition of MLM Medical Labs, a global central and specialty laboratory provider with operations in the United States, Germany, and South Africa. The deal establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents, expanding its global central laboratory and biomarker capabilities for clinical trials.
Why it matters — The acquisition strengthens Labcorp's global clinical trial and biomarker testing footprint, expanding its capacity and geographic reach for central laboratory services.
Zacks Investment Research has identified Labcorp Holdings (LH) as a top value stock for the long term, based on its Zacks Style Scores framework for selecting strong, market-beating stocks.
Why it matters — A LH watcher would care because the designation as a top long-term value stock signals favorable recognition of the company within a widely followed stock-selection methodology.
Zacks Investment Research highlighted Labcorp Holdings (LH) as a strong momentum stock, noting that its Style Scores tool helps investors identify top-rated stocks based on investing style. The piece points to LH's momentum characteristics as a reason for attention.
Why it matters — A LH watcher would care because the article positions Labcorp favorably among momentum-oriented stocks, potentially signaling positive market perception.
The 18 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $350, with estimates ranging from $293 to $385. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 86 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, Labcorp Holdings, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +9.0% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 86 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $293 to $385 over the next 12 months.
Labcorp Holdings, Inc. returned +16.6% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development.
The most recent item we track (Business Wire, 9 Sept 2026): "Great Point Partners III Sells MLM Medical Labs to Labcorp". Great Point Partners announced it has sold its portfolio company MLM Medical Labs, a provider of global central and specialty lab services supporting clinical trials, biomarker testing, and drug development, to Labcorp.
Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.
CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com
